Login to Your Account



Building on Combo's Success

Atripla Play: Gilead Taps NNRTI from Tibotec for New HIV Pill

By Jennifer Boggs


Monday, July 20, 2009
Hoping to improve on the success of Atripla - and extend the patent life of its lucrative HIV franchise - Gilead Sciences Inc. partnered with Tibotec Pharmaceuticals Ltd. to develop another three-in-one pill combining its Truvada with Tibotec's late-stage non-nucleoside reverse transcriptase inhibitor TMC278. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription